Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?

Executive Summary

Bowing to public pressure and following an unusual intervention by FDA, KV Pharmaceuticals announced April 1 it has cut the list price of its new preterm birth prevention drug Makena (hydroxyprogesterone caproate) by 54% – from $1,500 to $690 per injection – effective immediately.

You may also be interested in...



The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure

The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.

FDA’s Nonenforcement Actions Are Not Reviewable, Agency Argues In KV’s Makena Suit

The agency says its decisions not to take enforcement action against pharmacies compounding hydroxyprogesterone are discretionary and that KV has not shown that payers are likely to change their reimbursement policies if the court follows its request.

Makena’s Orphan Exclusivity Is “Nullified” By FDA’s Compounding Policy, KV Suit Says

KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel